What is the first-line treatment for gonorrhea?

The first-line treatment for gonorrhea is typically a single intramuscular injection of ceftriaxone at a dosage of 1 gram. Ceftriaxone is a third-generation cephalosporin antibiotic that is effective against Neisseria gonorrhoeae, the bacteria responsible for gonorrhea. This treatment is preferred due to ceftriaxone's potent activity against the organism, as well as its pharmacokinetic properties that allow for effective concentrations in the genital mucosa.

Using ceftriaxone as a first-line treatment is supported by clinical guidelines and reflects the need for effective and reliable options given the rising rates of antibiotic resistance observed in gonorrhea. The choice of a single-dose regimen also simplifies treatment adherence for patients.

Other treatments such as oral azithromycin are not considered first-line due to concerns about resistance patterns and efficacy. Additionally, intravenous antibiotics would typically be reserved for more severe or complicated cases rather than standard uncomplicated gonorrhea, and topical ointments are not used for this systemic infection. Thus, selecting intramuscular ceftriaxone is well-supported by current clinical practice and antimicrobial stewardship efforts.